A Topical Route to Neuroprotection?

May 22, 2026

The Ophthalmologist

Overview

Topical administration of the peptide JGRi1 shows promise in mitigating retinal degeneration in preclinical models. This approach targets a specific presynaptic mechanism rather than broadly blocking NMDA receptors, potentially offering a new therapeutic avenue for retinal neurodegenerative diseases.

Background

Neuroprotection in retinal diseases, particularly glaucoma, is an area of growing interest as traditional treatments focus primarily on lowering intraocular pressure. The ability to deliver neuroprotective agents topically could enhance patient compliance and treatment efficacy. Current neuroprotective strategies have not yet demonstrated sufficient clinical efficacy to be incorporated into standard management, making this research particularly relevant.

Data Highlights

Model	Effect of JGRi1
Ex vivo optic nerve cut	Preserved RGC survival, reduced apoptosis
In vivo NMDA injury	Improved RGC survival, reduced retinal glutamate accumulation

Key Findings

Topical JGRi1 penetrated the mouse retina and accumulated in the ganglion cell layer.
JGRi1 mitigated retinal degeneration in both ex vivo and in vivo models of retinal injury.
The peptide reduced cleaved caspase-3 levels and JNK2/STX1A phosphorylation.
JGRi1 decreased glutamate levels and SNARE complex formation.
There was a reduction in microglial infiltration, suggesting anti-inflammatory effects.

Clinical Implications

The findings suggest that topical delivery of JGRi1 could be a viable strategy for neuroprotection in retinal diseases, potentially improving patient adherence to treatment. Further research is needed to evaluate long-term efficacy and safety in humans.

Conclusion

This study presents a novel approach to retinal neuroprotection through topical administration of JGRi1, warranting further investigation to validate its clinical applicability.